Cryptococcosis

Organism

C. neoformans — encapsulated yeast, LARGEST polysaccharide capsule among medical fungi = major virulence factor (antiphagocytic, cf. bacterial capsules). Enables India ink visualization + antigen tests.

C. gattii: distinct species, eucalyptus tree niche (tropical/subtropical, expanding to temperate e.g. Pacific NW). KEY DISTINCTION: causes disease in IMMUNOCOMPETENT hosts more often than neoformans — specifically testable.

Transmission

Soil enriched by BIRD (pigeon) droppings — droppings = nutrient substrate, birds NOT infected themselves. Inhalation of aerosolized yeast/spores → initial pulmonary infection.

Pathogenesis

CMI-status determines everything (same pattern: TB, PCP, IPA). Intact CMI → contained/latent. Impaired CMI (HIV/AIDS low CD4 = classic) → hematogenous dissemination with STRIKING CNS TROPISM → cryptococcal meningitis (dominant clinical face of disease despite lung being true portal of entry).

Clinical

Pulmonary: asymptomatic nodule (immunocompetent, contained) → symptomatic pneumonia (immunocompromised). Disseminated: meningitis (most feared) + skin (umbilicated papules — mimics molluscum contagiosum in HIV+ patient, useful overlap point) + bone.

Diagnosis

CrAg (cryptococcal antigen) test: latex agglutination or lateral-flow immunoassay, serum/CSF — MORE sensitive, preferred PRIMARY test. WHO recommends ROUTINE CrAg SCREENING in advanced HIV (low CD4) even pre-symptomatic — pre-emptive treatment of antigenemia reduces meningitis progression. Proactive screening strategy, unlike most other reactive/symptom-triggered diagnoses in curriculum. Culture: Sabouraud’s / niger seed (bird seed) agar — selective, phenol-oxidase → brown color (see General Mycology). Confirms species (neoformans vs gattii). India ink: negative stain, capsule excludes ink → clear halo. Classic CSF test, imperfect sensitivity (low burden) — now generally supplanted by CrAg where available.

Treatment

Staged (structure mirrors TB/Melioidosis, different drugs):

Induction: Amphotericin B + flucytosine (~2wk) — combo superior fungicidal, less relapse
Consolidation → 3. Maintenance/suppression: Fluconazole, months, until CD4 recovery on ART allows stop. Same principle as PCP/Cryptosporidiosis: durable cure = restore host CMI, not just kill organism.

KEY MANAGEMENT POINT: ART initiation DELAYED several weeks after starting antifungals in HIV-associated meningitis — avoids IRIS (immune reconstitution inflammatory syndrome) = paradoxical worsening from recovering immune system attacking residual antigen. Analogous logic (not mechanism) to Jarisch-Herxheimer (Syphilis/Relapsing Fever) — treatment-triggered immunologic event, not organism activity, drives deterioration.

The Organism

Cryptococcus neoformans (and the related C. gattii, genuinely notable as a distinct species capable of causing disease in immunocompetent hosts, discussed further below) is an encapsulated yeast — its polysaccharide capsule, the largest and most prominent among medically important fungi, is the organism’s defining virulence factor, directly analogous in function (antiphagocytic protection) to the bacterial capsules covered under Bacterial Morphology and Physiology and Pneumococcal Pneumonia, and is what makes the organism visible by the classic India ink negative-stain technique (below) and detectable by the antigen tests that dominate modern Cryptococcus diagnosis.

Environmental Niche and Transmission

C. neoformans is found worldwide in soil, particularly soil enriched by bird droppings (pigeon droppings are the classically cited source, though the organism itself doesn’t infect birds — it simply uses their droppings as a nutrient-rich environmental growth substrate) — infection is acquired by inhaling aerosolized yeast cells or spores from this contaminated soil/dust, establishing an initial, usually subclinical or mild pulmonary infection before potential dissemination. C. gattii, by genuine contrast, is classically associated with specific eucalyptus tree ecological niches (historically concentrated in tropical/subtropical regions, though genuinely notable for an expanding geographic range including temperate areas like the Pacific Northwest of North America in recent decades) and, importantly, more often causes disease in immunocompetent hosts than C. neoformans does — a real, specifically testable species-level distinction worth remembering precisely.

Pathogenesis and the Central Role of Immune Status

As with several other organisms covered in this respiratory section (TB, PCP, invasive aspergillosis), Cryptococcus’s clinical behaviour is overwhelmingly determined by host cell-mediated immune status — initial pulmonary infection is typically contained and cleared (or rendered latent) by an intact CMI response in an immunocompetent host, while impaired CMI, most classically advanced HIV/AIDS with a low CD4 count, allows the organism to disseminate haematogenously from the lung, with a genuinely striking, specific tropism for the central nervous system — cryptococcal meningitis (covered under Central Nervous System Infections) represents this dissemination’s most feared and clinically dominant consequence, to the point that cryptococcal disease is often discussed and taught primarily through its meningeal presentation despite the lung being the actual portal of entry and initial infection site in every case.

Clinical Manifestations

Pulmonary cryptococcosis ranges from asymptomatic, incidentally discovered nodules (in an immunocompetent host whose intact CMI has successfully contained the infection, mirroring the latent-TB-like containment pattern covered under Tuberculosis) to a symptomatic pneumonia (cough, chest pain, fever) in a minority, with severity and dissemination risk both rising sharply with impaired immune status, exactly mirroring the CMI-dependence pattern established above. Disseminated disease, overwhelmingly in the immunocompromised, most commonly and most seriously manifests as cryptococcal meningitis — but skin (umbilicated papules, genuinely resembling molluscum contagiosum closely enough to cause diagnostic confusion in an HIV-positive patient, a specifically useful clinical point of overlap worth remembering), bone, and other organs can also be involved with haematogenous spread.

Laboratory Diagnosis

Cryptococcal antigen (CrAg) testing — by latex agglutination or, increasingly, a lateral-flow immunochromatographic assay — detects the capsular polysaccharide antigen directly in serum or CSF, and is the preferred, substantially more sensitive primary diagnostic method, genuinely important enough that WHO recommends routine CrAg screening in advanced HIV patients (CD4 below a defined threshold) even before any symptoms of meningitis develop, since asymptomatic cryptococcal antigenaemia identified and treated pre-emptively at this stage meaningfully reduces progression to overt, harder-to-treat meningitis — a genuinely important, proactive screening strategy distinct from the reactive, symptom-triggered diagnostic approach used for most other infections covered in this curriculum. Culture on Sabouraud’s dextrose agar, or the Cryptococcus-selective niger seed (bird seed) agar (see General Mycology — the organism’s phenol-oxidase activity turns this medium brown, a distinctive selective/differential feature), confirms diagnosis and allows species-level distinction (neoformans versus gattii) and susceptibility assessment where needed. India ink preparation — a negative-stain technique in which the large polysaccharide capsule excludes the ink particles, producing a distinctive clear halo around the yeast cell against the dark background — remains the classic, rapid bedside/laboratory technique, historically most associated with direct CSF examination in suspected cryptococcal meningitis, though genuinely limited by imperfect sensitivity, particularly in patients with a lower organism burden, and now generally supplanted by CrAg testing where available.

Treatment

Management is genuinely staged, mirroring in structure (though not identical in specific drugs) the staged treatment approach covered under Tuberculosis and Melioidosis: an induction phase using amphotericin B plus flucytosine (combination therapy for the most severe, particularly meningeal, disease, given superior fungicidal activity and reduced relapse compared with either agent alone) for roughly 2 weeks, followed by a consolidation phase and then a prolonged maintenance/suppressive phase using fluconazole, continued for an extended period (often months) until sustained immune reconstitution (in the HIV-associated context, CD4 recovery on effective antiretroviral therapy) makes discontinuation safe — directly echoing the same “durable cure depends on restoring host CMI, not just killing the organism” principle already established under Pneumocystis Pneumonia and Cryptosporidiosis. A genuinely important, specific management point in HIV-associated cryptococcal meningitis: antiretroviral therapy initiation is deliberately delayed for several weeks after starting antifungal treatment, to avoid precipitating immune reconstitution inflammatory syndrome (IRIS) — a paradoxical clinical worsening from the rapidly recovering immune system mounting an intense inflammatory response against residual cryptococcal antigen, genuinely analogous in underlying logic (though a distinct specific mechanism) to the Jarisch-Herxheimer reaction covered under Syphilis and Relapsing Fever, in that a treatment-related immunological event, not ongoing organism activity, drives the clinical deterioration.